Bioxytran Reports $1.35 Million Net Loss in Q1 2025 Amid Increased R&D Spending

Bioxytran, Inc. reported a net loss of $1.35 million for the first quarter of 2025, a significant increase from the $560,522 loss recorded in the same period of 2024. The company's total operating expenses for the quarter were $515,142, down from $779,229 year-over-year, primarily due to a substantial reduction in general and administrative costs. Research and development expenses surged to $349,500, compared to just $27,000 in the prior year, reflecting intensified efforts in product development, particularly for its lead drug candidate, BXT-25, aimed at treating hypoxic conditions.

The company's financial position showed a decline in total assets, which decreased to $136,052 from $138,694 at the end of 2024. Current liabilities, however, rose sharply to $2.84 million from $1.93 million, driven by increased accounts payable and a significant rise in derivative liabilities, which reached $991,404. This increase in liabilities contributed to a growing stockholders' deficit, which stood at $2.71 million as of March 31, 2025, compared to $1.79 million at the end of the previous fiscal year.

Strategically, Bioxytran has made notable advancements, including the completion of clinical trial recruitment for its ProLectin-M study in India, with results expected to be published within 90 days. The company also acquired minority interests in its subsidiary Pharmalectin, enhancing its control over its product pipeline. Additionally, Bioxytran is actively pursuing funding opportunities, aiming to raise approximately $3.7 million to support its operations and development activities over the next 15 months.

Operationally, the company has not generated any revenue since its inception and continues to rely on external funding to sustain its research and development efforts. As of March 31, 2025, Bioxytran had cash reserves of only $4,348, down from $5,154 at the end of 2024, raising concerns about its liquidity and ability to meet operational needs. The company is exploring private placements and other financing options to bolster its capital base, but it acknowledges the uncertainty surrounding the availability of such funds.

Looking ahead, Bioxytran's management has expressed optimism about the potential of its drug candidates, particularly BXT-25, which is designed to address critical medical needs in stroke treatment. However, the company faces substantial challenges, including the need for significant capital to continue its operations and the inherent risks associated with drug development. The outlook remains contingent on successful fundraising efforts and the outcomes of ongoing clinical trials.